|Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA||Founder & Exec. Chairman||124.01k||N/A||1972|
|Dr. Kunwar Shailubhai||CEO, Chief Scientific Officer & Exec. Director||300k||N/A||1958|
|Mr. Tiziano Lazzaretti||Chief Financial Officer||141.34k||N/A||1959|
|Dr. Fayez M. Hamzeh M.D., Ph.D.||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
|Dr. Andrea Brancale||Scientific Founder||N/A||N/A||N/A|
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops TZLS-501, a human anti-interleukin-6 receptor monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Tiziana Life Sciences PLC’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.